/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

M

Martin Wermke

Hebron University(PS)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

298

Papers

8.1K

Citations

43

h-index

107

i10-index

Martin Wermke is an academic researcher from Hebron University. The author has contributed to research in topics: CAR-T cell therapy research & Acute Myeloid Leukemia Research & Cancer Immunotherapy and Biomarkers. The author has an h-index of 43, co-authored 254 publications.

ORCID: 0000-0002-4844-4087

Research Topics

CAR-T cell therapy research Acute Myeloid Leukemia Research Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Research Studies

Papers by this author

works

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

2022 · Journal for ImmunoTherapy of Cancer · 285 citations

https://doi.org/10.1136/jitc-2022-005755

Jason Chesney Karl D. Lewis Harriet M. Kluger Omid Hamid

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

2021 · Leukemia · 172 citations

https://doi.org/10.1038/s41375-021-01328-9

David P. Steensma Martin Wermke Virginia M. Klimek Peter L. Greenberg

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)

2022 · Annals of Oncology · 87 citations

https://doi.org/10.1016/j.annonc.2022.02.225

Melanie Janning Juliane Süptitz Corinna Albers Pierre Delpy

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

2022 · ESMO Open · 83 citations

https://doi.org/10.1016/j.esmoop.2022.100639

Elena Garralda Ammar Sukari Nehal J. Lakhani Akash Patnaik

Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations

2021 · Journal of Thoracic Oncology · 59 citations

https://doi.org/10.1016/j.jtho.2021.06.025

Felix Carl Saalfeld Carina Wenzel Petros Christopoulos Sabine Merkelbach‐Bruse

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma

2021 · Cancer Immunology Immunotherapy · 50 citations

https://doi.org/10.1007/s00262-021-02981-w

Jan Budczies Martina Kirchner Klaus Kluck Daniel Kazdal

Research topics

topics

CAR-T cell therapy research

Acute Myeloid Leukemia Research

Cancer Immunotherapy and Biomarkers

Lung Cancer Treatments and Mutations

Lung Cancer Research Studies

Chat about Author

Papers

Chat

Click to start Chat